

Isamu Okamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2174695/publications.pdf>

Version: 2024-02-01

196
papers

14,365
citations

87723

38
h-index

21474

114
g-index

197
all docs

197
docs citations

197
times ranked

12488
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2022, 23, e285-e288.	1.1	12
2	Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	1.7	31
3	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIa Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). <i>Journal of Clinical Oncology</i> , 2022, 40, 231-241.	0.8	61
4	Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. <i>Journal of Clinical Oncology</i> , 2022, 40, 180-188.	0.8	21
5	Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. <i>European Journal of Cancer</i> , 2022, 162, 99-106.	1.3	30
6	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)., 2022, 10, e004025.		22
7	The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. <i>PLoS ONE</i> , 2022, 17, e0263247.	1.1	8
8	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 342.	1.1	2
9	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. <i>European Respiratory Journal</i> , 2022, 60, 2200380.	3.1	34
10	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	1.3	4
11	A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 503.	1.1	10
12	A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non-small cell lung cancer: TORG1937 (DATE study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8536-8536.	0.8	4
13	A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non-small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9097-9097.	0.8	1
14	Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase III J025567 study. <i>Thoracic Cancer</i> , 2022, 13, 2192-2200.	0.8	5
15	Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. <i>Oncologist</i> , 2022, 27, 720-e702.	1.9	6
16	Predictive model of the prognosis in non-small cell lung cancer treated with first-line immunotherapy based on machine learning.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21125-e21125.	0.8	0
17	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. <i>European Journal of Cancer</i> , 2022, 172, 199-208.	1.3	9
18	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). <i>Clinical Lung Cancer</i> , 2021, 22, 147-151.	1.1	16

#	ARTICLE	IF	CITATIONS
19	<i>Scedosporium apiospermum</i> lung disease in a patient with nontuberculous mycobacteria. <i>Respirology Case Reports</i> , 2021, 9, e00691.	0.3	3
20	Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR mutant non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 114-116.	0.8	5
21	Predicting osimertinib treatment outcomes through EGFR mutant fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). <i>Molecular Oncology</i> , 2021, 15, 126-137.	2.1	12
22	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 152, 27-33.	0.9	35
23	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021, 149, 473-482.	2.3	35
24	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1073-1082.	1.0	9
25	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 144-150.	0.9	9
26	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. <i>European Journal of Cancer</i> , 2021, 149, 14-22.	1.3	30
27	Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study. <i>Journal of Clinical Oncology</i> , 2021, 39, e21125-e21125.	0.8	0
28	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2475-2486.	1.3	13
29	Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021, 11, 12732.	1.6	7
30	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). <i>Clinical Lung Cancer</i> , 2021, 22, 601-606.	1.1	31
31	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). <i>Clinical Lung Cancer</i> , 2021, 22, 276-289.	1.1	6
32	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. <i>Scientific Reports</i> , 2021, 11, 15057.	1.6	17
33	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 4835-4848.	0.4	31
34	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. <i>Lung Cancer</i> , 2021, 158, 156-161.	0.9	4
35	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage SCLC: Results From the Phase 3 MERU Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1570-1581.	0.5	65
36	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1523-1532.	0.5	57

#	ARTICLE	IF	CITATIONS
37	Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. <i>Clinical Lung Cancer</i> , 2021, 22, e784-e785.	1.1	2
38	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010.	1.7	6
39	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	0.5	108
40	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	1.6	38
41	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1745-1753.	2.0	1
42	A long-term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non-squamous non-small cell lung cancer. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 927-931.	0.2	1
43	Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: Nlke Trial (LOGiK2004). <i>Cancer Management and Research</i> , 2021, Volume 13, 8489-8493.	0.9	4
44	The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. <i>Nature</i> , 2021, 600, 319-323.	13.7	37
45	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). <i>Cancer Management and Research</i> , 2021, Volume 13, 9167-9173.	0.9	5
46	Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer</i> , 2020, 126, 219-227.	2.0	20
47	Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 475.	1.9	4
48	Survival Analysis for Patients with <i>ALK</i> Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. <i>Oncologist</i> , 2020, 25, 306-e618.	1.9	12
49	Therapies after first-line afatinib in patients with <i>EGFR</i> ⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. <i>Future Oncology</i> , 2020, 16, 49-60.	1.1	4
50	Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating <i>EGFR</i> Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, e21-e24.	1.1	4
51	Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. <i>Lung Cancer</i> , 2020, 140, 8-18.	0.9	56
52	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803.	0.8	28
53	HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors. <i>Cancer Science</i> , 2020, 111, 3395-3396.	1.7	2
54	Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). <i>ESMO Open</i> , 2020, 5, e000656.	2.0	4

#	ARTICLE	IF	CITATIONS
55	Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. <i>Diagnostics</i> , 2020, 10, 949.	1.3	13
56	Association of Mps one binder kinase activator 1 (<scp>MOB1</scp> expression with poor disease-free survival in individuals with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2830-2839.	0.8	4
57	A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1935-1942.	0.5	50
58	A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). <i>BMC Cancer</i> , 2020, 20, 370.	1.1	8
59	A randomized phase 3 study of maintenance therapy with Sâ€ plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sâ€ for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). <i>Cancer</i> , 2020, 126, 3648-3656.	2.0	2
60	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2187-2196.	0.8	78
61	Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2639-2650.	1.2	10
62	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 472-476.	1.1	12
63	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. <i>Lung Cancer</i> , 2020, 145, 18-26.	0.9	57
64	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. <i>Lung Cancer</i> , 2020, 146, 97-104.	0.9	21
65	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , 2020, 146, 160-164.	0.9	6
66	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e196828.	3.4	48
67	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1657-1669.	0.5	395
68	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020, 20, 103.	1.1	14
69	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	1.2	42
70	<p>Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-small Cell Lung Cancer: Emerging Mechanisms and Perspectives</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 10, 161-170.	1.3	7
71	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. <i>Clinical Lung Cancer</i> , 2020, 21, e84-e88.	1.1	35
72	Plasma screening for the T790M mutation of <i>EGFR</i> and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. <i>Cancer</i> , 2020, 126, 1940-1948.	2.0	18

#	ARTICLE	IF	CITATIONS
73	Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy. <i>International Journal of Cancer</i> , 2020, 147, 2327-2334.	2.3	5
74	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. <i>International Immunology</i> , 2020, 32, 547-557.	1.8	18
75	A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. <i>Cancer Science</i> , 2020, 111, 1685-1691.	1.7	22
76	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. <i>Cancer Science</i> , 2020, 111, 2482-2487.	1.7	14
77	Molecularly-targeted Therapies for Advanced Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 877-880.	0.0	0
78	Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. <i>Cancer Science</i> , 2019, 110, 2884-2893.	1.7	22
79	Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). <i>Clinical Lung Cancer</i> , 2019, 20, 469-476.e1.	1.1	26
80	Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100889.	0.2	1
81	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 145-150.	0.9	18
82	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. <i>Respiratory Investigation</i> , 2019, 57, 512-533.	0.9	36
83	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. <i>Lung Cancer</i> , 2019, 138, 58-64.	0.9	3
84	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6644-6652.	3.2	100
85	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 13362.	1.6	39
86	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0217991.	1.1	5
87	Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). <i>Lung Cancer</i> , 2019, 132, 1-8.	0.9	10
88	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637.	1.4	25
89	Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 1916-1924.	0.7	25
90	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1925-1933.	0.7	23

#	ARTICLE	IF	CITATIONS
91	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. <i>International Journal of Clinical Oncology</i> , 2019, 24, 485-493.	1.0	4
92	Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor. <i>European Journal of Radiology Open</i> , 2019, 6, 72-77.	0.7	11
93	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019, 131, 128-133.	0.9	18
94	Mondor's Disease of the Chest Wall. <i>Internal Medicine</i> , 2019, 58, 3349-3349.	0.3	0
95	Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. <i>Oncologist</i> , 2019, 24, 1022-1026.	1.9	16
96	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 29-36.	0.6	101
97	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i> , 2019, 14, 99-106.	0.5	82
98	Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. <i>Respiratory Investigation</i> , 2019, 57, 27-33.	0.9	10
99	Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. <i>Lung Cancer</i> , 2019, 130, 5-9.	0.9	44
100	Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIa non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8501-8501.	0.8	11
101	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9003-9003.	0.8	3
102	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9020-9020.	0.8	39
103	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9031-9031.	0.8	8
104	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9125-TPS9125.	0.8	3
105	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 671-677.	0.5	4
106	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9038-9038.	0.8	0
107	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8557-8557.	0.8	2
108	Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8529-8529.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).. Journal of Clinical Oncology, 2019, 37, e20531-e20531.	0.8	0
110	Molecularly-targeted Therapies for Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1115-1118.	0.0	0
111	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Japanese Journal of Clinical Oncology, 2018, 48, 367-375.	0.6	26
112	Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. Cancer Science, 2018, 109, 1177-1184.	1.7	10
113	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surgical Oncology, 2018, 27, 88-94.	0.8	41
114	Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. Lung Cancer, 2018, 120, 98-107.	0.9	23
115	Anticancer drug treatment for advanced lung cancer with interstitial lung disease. Respiratory Investigation, 2018, 56, 307-311.	0.9	17
116	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer, 2018, 118, 36-40.	0.9	81
117	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	0.9	63
118	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 267-276.	1.1	14
119	Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer, 2018, 115, 116-120.	0.9	76
120	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 926-937.	0.5	27
121	Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	1.1	44
122	Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study. British Journal of Pharmacology, 2018, 175, 29-37.	2.7	16
123	Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Safety, 2018, 41, 229-237.	1.4	48
124	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
125	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	0.8	515
126	Exploration of resistance mechanisms for epidermal growth factor receptor tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer Science, 2018, 109, 3921-3933.	1.7	27

#	ARTICLE	IF	CITATIONS
127	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. <i>Lung Cancer</i> , 2018, 126, 156-161.	0.9	3
128	Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 136-141.	0.9	14
129	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5897-5901.	0.5	17
130	Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5903-5907.	0.5	11
131	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	0.6	4
132	Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. <i>Cancer Science</i> , 2018, 109, 3657-3661.	1.7	12
133	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. <i>Thoracic Cancer</i> , 2018, 9, 1519-1521.	0.8	17
134	Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial. <i>Cancer Science</i> , 2018, 109, 1930-1938.	1.7	53
135	Metastatic Lung Adenocarcinoma Mimicking Meningioma. <i>Internal Medicine</i> , 2018, 57, 1057-1058.	0.3	0
136	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. <i>Journal of Clinical Oncology</i> , 2018, 36, 9007-9007.	0.8	53
137	Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non-small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR. <i>Journal of Clinical Oncology</i> , 2018, 36, e21073-e21073.	0.8	7
138	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018, 9, 30587-30593.	0.8	18
139	Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 553-557.	0.5	19
140	Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 937-941.	0.9	4
141	Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu A1401). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1161-1166.	0.5	42
142	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 75-82.	0.9	37
143	Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, e46-e47.	0.5	7
144	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , 2017, 18, 719-723.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Respiratory Investigation</i> , 2017, 55, 181-183.	0.9	4
146	CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. <i>Lung Cancer</i> , 2017, 113, 72-78.	0.9	9
147	Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. <i>Lung Cancer</i> , 2017, 112, 230-231.	0.9	22
148	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 1843-1849.	1.7	40
149	Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 100-103.	1.1	9
150	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. <i>Oncotarget</i> , 2017, 8, 72127-72132.	0.8	14
151	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. <i>Oncotarget</i> , 2017, 8, 68123-68130.	0.8	63
152	Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 4223-4228.	0.5	30
153	Do infections with disseminated <i>Mycobacterium avium</i> complex precede sweet's syndrome? A case report and literature review. <i>International Journal of Mycobacteriology</i> , 2017, 6, 336.	0.3	8
154	Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9027-9027.	0.8	0
155	5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 1117-1124.	0.0	0
156	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (ESTAR): A phase II, randomized, controlled, open-label, multicenter, phase II trial. <i>Cancer</i> , 2016, 122, 1050-1059.	2.0	35
157	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. <i>Lung Cancer</i> , 2016, 101, 1-8.	0.9	118
158	FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. <i>Cancer Science</i> , 2016, 107, 1667-1676.	1.7	31
159	Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1586-1590.	0.5	11
160	Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. <i>Lung Cancer</i> , 2016, 99, 41-45.	0.9	28
161	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. <i>ESMO Open</i> , 2016, 1, e000063.	2.0	37
162	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 462-467.	0.6	54

#	ARTICLE	IF	CITATIONS
163	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. <i>Gastric Cancer</i> , 2016, 19, 687-695.	2.7	37
164	Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20503-e20503.	0.8	0
165	Beau's Lines and Mees' Lines Formations after Chemotherapy. <i>Internal Medicine</i> , 2015, 54, 2281-2281.	0.3	5
166	Falciparum Malaria Incidentally Pretreated with Azithromycin. <i>Internal Medicine</i> , 2015, 54, 2513-2516.	0.3	0
167	Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non-Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples. <i>Journal of Thoracic Oncology</i> , 2015, 10, 800-805.	0.5	24
168	Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. <i>Investigational New Drugs</i> , 2015, 33, 1148-1150.	1.2	16
169	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. <i>Oncotarget</i> , 2015, 6, 30850-30858.	0.8	72
170	Clinical development of nintedanib for advanced non-small-cell lung cancer. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1701.	0.9	10
171	Nicotine induces resistance to erlotinib via cross-talk between $\alpha 1$ nAChR and EGFR in the non-small cell lung cancer xenograft model. <i>Lung Cancer</i> , 2015, 88, 1-8.	0.9	30
172	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4014-4021.	3.2	392
173	Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1225-1233.	1.1	6
174	Successful treatment with alectinib after crizotinib-induced esophageal ulceration. <i>Lung Cancer</i> , 2015, 88, 349-351.	0.9	6
175	Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. <i>Oncology Letters</i> , 2015, 9, 405-410.	0.8	5
176	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 74-79.	0.9	157
177	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer. <i>Cancer Genetics</i> , 2015, 208, 271-278.	0.2	12
178	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8073-8073.	0.8	6
179	Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. <i>Oncotarget</i> , 2015, 6, 20466-20473.	0.8	32
180	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8056-8056.	0.8	0

#	ARTICLE	IF	CITATIONS
181	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. <i>Oncotarget</i> , 2014, 5, 11847-11856.	0.8	61
182	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 375.	1.0	22
183	A Phase I Study of Split-dose Cisplatin and Etoposide with Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy in Elderly Patients with Limited-disease Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 743-748.	0.6	4
184	Current status and future perspectives of cooperative study groups for lung cancer in Japan. <i>Respiratory Investigation</i> , 2014, 52, 339-347.	0.9	3
185	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1236-1244.	5.1	678
186	Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement. <i>Lung Cancer</i> , 2014, 83, 302-304.	0.9	23
187	Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8117-8117.	0.8	36
188	PICT1 expression is a poor prognostic factor in non-small cell lung cancer. <i>Oncoscience</i> , 2014, 1, 375-382.	0.9	16
189	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. <i>Oncotarget</i> , 2014, 5, 2293-2304.	0.8	32
190	Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8095-8095.	0.8	0
191	Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19078-e19078.	0.8	0
192	Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2062.	0.8	676
193	A Juvenile Case of Pulmonary Lymphangitic Carcinomatosis Caused by Sigmoid Colon Cancer with a Component of Micropapillary Carcinoma. <i>Internal Medicine</i> , 2011, 50, 2361-2365.	0.3	16
194	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5240-5246.	0.8	161
195	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 121-128.	5.1	3,794
196	Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs. <i>Journal of the National Cancer Institute</i> , 1998, 90, 307-315.	3.0	60